FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702610> ?p ?o ?g. }

• W4385702610 endingPage "e33877d7" @default.
• W4385702610 startingPage "e33877d7" @default.
• W4385702610 abstract "Topic: 28. Enzymopathies, membranopathies and other anemias Background: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia. Although there is consensus on an increased risk of thromboembolic events (TEs) in patients with CAD than those without CAD, the evidence on mortality is mixed and the association of both risks with the time since disease diagnosis and biomarker levels has been rarely assessed. Aims: This study evaluated whether patients with CAD have higher risk of mortality and TEs compared with a matched non-CAD population at various time periods since diagnosis. The association between biomarker levels (hemoglobin [Hb], bilirubin, and lactate dehydrogenase [LDH]) and the risk of mortality and TEs in CAD patients was also assessed. Methods: This was a retrospective, cohort study of CAD patients and exact-matched non-CAD patients in the US, identified using the OPTUM® de-identified Electronic Health Record dataset (2007-2021). Mortality and TEs were assessed over the full follow-up period (till the end of medical activity, study period, or death) and at pre-defined time periods (100 days, 1 year, 2 years, 3 years, 5 years, and 10 years) from CAD diagnosis. Biomarker levels were assessed during follow-up, and categorized as follows: bilirubin: severe, >2.4 mg/dL; moderate, >1.2─≤2.4 mg/dL; normal, ≤1.2 mg/dL, LDH: severe, >500 U/L; moderate, >250─≤500 U/L; normal, ≤250 U/L, Hb: no anemia, Hb ≥12 g/dL; mild, Hb ≥10─<12 g/dL; moderate, Hb ≥8─<10 g/dL; and severe, Hb <8 g/dL. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CI) were obtained for the pre-defined time periods using multivariate cox proportional hazards regression analyses. Time-varying cox regressions were used in the CAD cohort to analyze the association between biomarkers (all observations until event) and risk of mortality or TE. Results: Overall, 457 patients with CAD and 2285 exact-matched non-CAD patients were included. The mortality and TE risks in CAD compared with non-CAD cohorts were significantly higher, particularly in the early periods after diagnosis (e.g., 100 day aHR [95% CI], mortality: 16.36 [6.83─39.19]; TE: 4.92 [3.22─7.45]; both P<0.001) compared with longer periods (e.g., 10 year aHR [95% CI], mortality: 2.26 [1.84─2.77]; TE: 2.08 [1.71─2.53]; both P<0.001) (Table 1). In the CAD cohort, patients with mild, moderate, or severe anemia had significantly higher risk of mortality than those without anemia (mild: aHR [95% CI]: 2.55 [1.40─4.65]; P=0.002; moderate: 7.00 [4.00─12.23]; and severe: 16.70 [9.14─30.34]; both P=0.001). Moderate and severe anemia were also correlated with higher risk of TEs compared with no anemia (aHR [95% CI]: 2.16 [1.28─3.64]; P=0.004 and 3.37 [1.81─6.26]; P=0.001, respectively). Severe bilirubin (aHR [95% CI]: 3.03 [1.98─4.64]; P=0.001) and severe LDH levels (aHR [95% CI]: 2.31 [1.29─4.13]; P=0.005) were associated with increased risk of mortality compared with normal levels. Summary/Conclusion: The clinical burden associated with CAD is significant and extends beyond anemia. Patients with CAD were twice more likely to die or experience TEs than those without CAD. These risks were particularly high in the early periods after diagnosis with mortality risk 16 times and TE risk 5 times higher in the first 100 days. Within the CAD cohort, severely deranged markers of hemolysis (LDH, bilirubin) and anemia were associated with increased mortality risk. Moderate and severe anemia were also associated with increased TE risk. Early and chronic control of complement activation and the resulting hemolysis in CAD may therefore help manage the risk of mortality and TEs.Keywords: Thromboembolic events, AIHA (see autoimmune hemolytic anemia), Hemoglobin, Mortality" @default.
• W4385702610 created "2023-08-10" @default.
• W4385702610 creator A5005731914 @default.
• W4385702610 creator A5018102572 @default.
• W4385702610 creator A5019989437 @default.
• W4385702610 creator A5031024904 @default.
• W4385702610 creator A5033634387 @default.
• W4385702610 creator A5051544503 @default.
• W4385702610 creator A5066373983 @default.
• W4385702610 creator A5088972525 @default.
• W4385702610 creator A5092619575 @default.
• W4385702610 date "2023-08-01" @default.
• W4385702610 modified "2023-09-27" @default.
• W4385702610 title "P1474: HEMOLYTIC MARKERS, MORTALITY, AND THROMBOEMBOLIC EVENTS IN CAD: RISK ASSESSMENT BY TIME PERIOD SINCE DIAGNOSIS" @default.
• W4385702610 doi "https://doi.org/10.1097/01.hs9.0000972780.33877.d7" @default.
• W4385702610 hasPublicationYear "2023" @default.
• W4385702610 type Work @default.
• W4385702610 citedByCount "0" @default.
• W4385702610 crossrefType "journal-article" @default.
• W4385702610 hasAuthorship W4385702610A5005731914 @default.
• W4385702610 hasAuthorship W4385702610A5018102572 @default.
• W4385702610 hasAuthorship W4385702610A5019989437 @default.
• W4385702610 hasAuthorship W4385702610A5031024904 @default.
• W4385702610 hasAuthorship W4385702610A5033634387 @default.
• W4385702610 hasAuthorship W4385702610A5051544503 @default.
• W4385702610 hasAuthorship W4385702610A5066373983 @default.
• W4385702610 hasAuthorship W4385702610A5088972525 @default.
• W4385702610 hasAuthorship W4385702610A5092619575 @default.
• W4385702610 hasBestOaLocation W43857026101 @default.
• W4385702610 hasConcept C126322002 @default.
• W4385702610 hasConcept C167135981 @default.
• W4385702610 hasConcept C181199279 @default.
• W4385702610 hasConcept C2776175824 @default.
• W4385702610 hasConcept C2777318727 @default.
• W4385702610 hasConcept C2777385706 @default.
• W4385702610 hasConcept C2777513400 @default.
• W4385702610 hasConcept C2778248108 @default.
• W4385702610 hasConcept C2781197716 @default.
• W4385702610 hasConcept C2908647359 @default.
• W4385702610 hasConcept C55493867 @default.
• W4385702610 hasConcept C71924100 @default.
• W4385702610 hasConcept C72563966 @default.
• W4385702610 hasConcept C86803240 @default.
• W4385702610 hasConcept C90924648 @default.
• W4385702610 hasConcept C99454951 @default.
• W4385702610 hasConceptScore W4385702610C126322002 @default.
• W4385702610 hasConceptScore W4385702610C167135981 @default.
• W4385702610 hasConceptScore W4385702610C181199279 @default.
• W4385702610 hasConceptScore W4385702610C2776175824 @default.
• W4385702610 hasConceptScore W4385702610C2777318727 @default.
• W4385702610 hasConceptScore W4385702610C2777385706 @default.
• W4385702610 hasConceptScore W4385702610C2777513400 @default.
• W4385702610 hasConceptScore W4385702610C2778248108 @default.
• W4385702610 hasConceptScore W4385702610C2781197716 @default.
• W4385702610 hasConceptScore W4385702610C2908647359 @default.
• W4385702610 hasConceptScore W4385702610C55493867 @default.
• W4385702610 hasConceptScore W4385702610C71924100 @default.
• W4385702610 hasConceptScore W4385702610C72563966 @default.
• W4385702610 hasConceptScore W4385702610C86803240 @default.
• W4385702610 hasConceptScore W4385702610C90924648 @default.
• W4385702610 hasConceptScore W4385702610C99454951 @default.
• W4385702610 hasIssue "S3" @default.
• W4385702610 hasLocation W43857026101 @default.
• W4385702610 hasLocation W43857026102 @default.
• W4385702610 hasOpenAccess W4385702610 @default.
• W4385702610 hasPrimaryLocation W43857026101 @default.
• W4385702610 hasRelatedWork W2001088022 @default.
• W4385702610 hasRelatedWork W2001582306 @default.
• W4385702610 hasRelatedWork W2043755836 @default.
• W4385702610 hasRelatedWork W2068919004 @default.
• W4385702610 hasRelatedWork W2133681212 @default.
• W4385702610 hasRelatedWork W2233254901 @default.
• W4385702610 hasRelatedWork W2368988603 @default.
• W4385702610 hasRelatedWork W2415583261 @default.
• W4385702610 hasRelatedWork W4220960064 @default.
• W4385702610 hasRelatedWork W4382678277 @default.
• W4385702610 hasVolume "7" @default.
• W4385702610 isParatext "false" @default.
• W4385702610 isRetracted "false" @default.
• W4385702610 workType "article" @default.